



23 October 2019

ASX ANNOUNCEMENT

IMPEDIMED ANNOUNCES PROGRAM TO END CANCER-RELATED LYMPHOEDEMA

Company launches website focused on education and prevention

Brisbane, Australia – ImpediMed Limited (ASX:IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), today announced the kickoff of the company's new, comprehensive Lymphoedema Prevention Program with the goal of ending cancer-related lymphoedema.

"Because lymphoedema is often incurable, many patients and even some healthcare providers don't realise it's actually preventable," said Chirag Shah, M.D., staff, Director of Breast Radiation Oncology/Clinical Research, Department of Radiation Oncology, Cleveland Clinic. "This vitally important effort will help provide cancer centres and physicians with the necessary tools to identify lymphoedema earlier and potentially reverse its progression, benefiting cancer survivors worldwide."

The Lymphoedema Prevention Program utilises ImpediMed's Test, Trigger, Treat™ protocol for early detection and intervention of cancer-related lymphoedema. Routine lymphoedema testing of cancer survivors uses the company's FDA-cleared SOZO® device with BIS (L-Dex®) technology, which measures extracellular fluid. A significant increase in a patient's L-Dex score is a trigger to evaluate the patient and initiate intervention.

ImpediMed's PREVENT Trial, the largest multi-site randomised controlled trial ever performed to study lymphoedema prevention, demonstrated that routine monitoring with L-Dex combined with at-home intervention resulted in a 95% reduction in lymphoedema progression at one year. Today, L-Dex is the only reliable, validated tool to detect subclinical lymphoedema. The company's SOZO digital health platform can measure a patient's L-Dex score with a simple, painless 30-second scan. Monitoring L-Dex scores allows clinicians across multiple specialties to provide individualised, proactive care that can help improve patient outcomes.

Currently, one in three at-risk cancer survivors will develop secondary lymphoedema related to their cancer treatment, costing the U.S. healthcare system approximately \$7 billion every year. The aim of this program is to help educate healthcare providers and patients that with the proper protocols in place, lymphoedema can be detected and managed before it becomes a debilitating chronic condition.

ImpediMed's new website, www.preventlymphoedema.com, is designed to highlight improvements in the early detection of lymphoedema. The site offers quick and easy access to extensive information about lymphoedema prevention including videos and educational materials for surgeons, cancer centres, caregivers and patients.

“Our program was developed to communicate with all of the relevant stakeholders involved in the early detection and prevention of lymphoedema,” said ImpediMed Chief Medical Officer, Dr. Frank Vicini. “As lymphoedema awareness grows, patients will favour cancer centres and surgical practices that offer effective and comprehensive prevention programs. By working together, we can stop the progression of lymphoedema.”

Contact Details

Richard Carreon
Managing Director & CEO

Media Contact:

Kyahn Williamson, WE Buchan

T: +61 3 9866 4722

E: kwilliamson@buchanwe.com.au

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure and lymphoedema, sold in select markets globally.

For more information, visit www.impedimed.com.

About BIS

Bioimpedance spectroscopy (BIS) differs fundamentally from other bioimpedance approaches. ImpediMed's BIS devices measure impedance at 256 different frequencies over a full spectrum from 3 kHz to 1000 kHz and do not depend upon population-specific prediction equations to generate fluid volumes or tissue masses. ImpediMed's BIS technology does not assume that extracellular fluid (ECF) and intracellular fluid (ICF) are uniformly distributed. Therefore, this technique provides a more direct and individualised measure of ECF, ICF, and total body water (TBW) compartments of the body compared with other approaches. This has significant advantages, particularly in-patient populations with altered fluid homeostasis.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.